Most Viewed Articles - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Most Viewed Articles

EMA Invites Comments on New Guidance for Vaccine Development

August 4, 2014

EMA has released the second module of a new guideline on influenza vaccines for a six-month public consultation. The guidance covers the non-clinical and clinical requirements for the development of new influenza vaccines and aims to facilitate the prompt assessment of new vaccines. It follows the publication of a module on the quality requirements.

FDA Issues Warning Letter to Italian API Manufacturer

July 16, 2014
PTSM: Pharmaceutical Technology Sourcing and Management

Trifarma cited for significant deviations in data collection and security, and employee training.

Hospira Acquires Orchid's API Manufacturing and R&D Facilities

July 9, 2014

PTSM: Pharmaceutical Technology Sourcing and Management

Hospira acquires assets from Orchid Chemicals & Pharmaceuticals for $218 million.

BMS Recalls Coumadin Vials Due to Particulate Matter

July 1, 2014

Bristol-Myers Squibb issues a voluntary US recall of Coumadin (warfarin sodium) for injection due to presence of particulate matter.

EMA Revises Guidance on Advanced Therapies

July 1, 2014

European Medicines Agency clarifies advanced-therapy medicinal products classification.

FDA Outlines Guidance and Rules for Compounding Drug Products

July 1, 2014

FDA releases guidance documents and rules on requirements for compounding human drug products.

FDA Issues Warning Letter to GSK Biologicals

June 26, 2014

GSK Biologicals receives warning about cGMP compliance issues at its Quebec facility.

National Bioscience Report Reveals Positive Trends for Bioscience Industry

June 25, 2014

According to the National Bioscience Report, the US bioscience industry is on course for continued growth.

Abbott to Acquire Russia's Veropharm

June 25, 2014

Abbott will acquire a controlling interest in the Russian pharmaceutical manufacturer Veropharm.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Click here